Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)

Short Bowel Syndrome Clinical Trial

Official title:

A Study of the Safety and Efficacy of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00172185
• Other study ID #: CL0600-005
• Secondary ID: 2004-000439-27
• Status: Completed
• Phase: Phase 3
• Start date: January 10, 2005
• Est. completion date: January 24, 2008

Study information

• Verified date: May 2021
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this clinical study is to evaluate the long-term safety and efficacy of daily administration of teduglutide.

Description:

Teduglutide is an analog of naturally occurring human glucagon-like peptide-2 (GLP-2), a peptide secreted by L-cells of the distal intestine. GLP-2 is known to increase intestinal and portal blood flow, and inhibit gastric acid secretion. Teduglutide binds to the glucagon-like peptide-2 receptors located in intestinal subpopulations of enteroendocrine cells, subepithelial myofibroblasts and enteric neurons of the submucosal and myenteric plexus. Activation of these receptors results in the local release of multiple mediators including insulin-like growth factor (IGF)-1, nitric oxide and keratinocyte growth factor (KGF). This multicenter, double-blind, international, Phase III trial will have a treatment period of 28 weeks. Subjects in this study are those who received teduglutide or placebo in protocol CL0600-004 (NCT00081458). These subjects will receive daily subcutaneous injections of 0.05 milligrams or 0.10 milligrams of teduglutide per kilogram of body weight. Subjects will have visits every 4 to 6 weeks and will be assessed for parenteral nutrition (PN) reduction with a follow-up period of 4 weeks duration for those subjects who do not complete this protocol, or do not enter into the long-term safety extension protocol CL0600-010.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 65
• Est. completion date: January 24, 2008
• Est. primary completion date: January 24, 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

At dosing week 24 of protocol CL0600-004 (NCT00081458), subjects will be reviewed for their participation in this study.

Subjects who meet all of the following criteria can be enrolled in this study:

• Signed and dated informed consent form (ICF) to participate before any study-related procedures are performed
• Completion of protocol CL0600-004 (NCT00081458)

Exclusion Criteria:

• History of cancer or clinically significant lymphoproliferative disease with fewer than 5 years documented disease-free state
• History of alcohol or drug abuse (within previous year)
• Prior use of native glucagon-like peptide 2 (GLP-2) within 3 months of screening visit
• Pregnant or lactating women
• Any condition or circumstance, which in the investigator's opinion would put the subject at any undue risk, prevent completion of the study, or interfere with analysis of the study results

Related Conditions & MeSH terms

• Short Bowel Syndrome
• Syndrome

Intervention

Drug:
• teduglutide 0.05 mg/kg/d
0.05 mg/kg/d subcutaneous injection
• teduglutide 0.10 mg/kg/d
0.10 mg/kg/d subcutaneous injection

Locations

Country	Name	City	State
Belgium	Hôpital Erasme	Brussels
Canada	St. Michael's Hospital	Toronto	Ontario
Canada	Toronto General Hospital	Toronto	Ontario
Canada	St. Paul's Hospital	Vancouver	British Columbia
Denmark	Rigshospitalet	Copenhagen
France	Hôpital Huriez	Lille
France	Hôpital de la Croix-Rousse	Lyon
France	Hôpital Lariboisière	Paris
Netherlands	Academic Medical Center, Department of Endocrinology & Metabolism	Amsterdam
Poland	Pracownia Zywienia	Olsztyn
Poland	Samodzielny Publiczny Szpital Kliniczny-Im.prof W.Orlowskiego CMKP	Warsaw
United Kingdom	St. Mark's Hospital	Harrow
United States	Albany Medical Center	Albany	New York
United States	Emory University Hospital	Atlanta	Georgia
United States	The Cleveland Clinic Foundation	Cleveland	Ohio
United States	University of Nebraska Medical Center	Omaha	Nebraska
United States	University of Pennsylvania - Penn Nursing	Philadelphia	Pennsylvania
United States	University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania
United States	Rhode Island Hospital	Providence	Rhode Island
United States	University of Rochester Medical Center	Rochester	New York
United States	Mayo Clinic Scottsdale	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Shire

Countries where clinical trial is conducted

United States,  Belgium,  Canada,  Denmark,  France,  Netherlands,  Poland,  United Kingdom, 

References & Publications (3)

Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B, O'Keefe SJ. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut. 2011 Jul;60(7):90 — View Citation

O'Keefe SJ, Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B. Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure. Clin Gastroenterol Hepatol. 2013 Jul;11(7):815-23.e1-3. doi: 10.1016/j. — View Citation

Vipperla K, O'Keefe SJ. Study of teduglutide effectiveness in parenteral nutrition-dependent short-bowel syndrome subjects. Expert Rev Gastroenterol Hepatol. 2013 Nov;7(8):683-7. doi: 10.1586/17474124.2013.842894. Epub 2013 Oct 17. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Subjects Achieving a 20% Reduction at Week 28	For those subjects who received teduglutide (0.05 or 0.10 mg dose) in Study 004 and the same in Study 005, Parenteral Nutrition (PN) Use at Week 28 was compared to the Baseline Visit of Study 004 to calculate the 20% reduction in PN Use. For those subjects who received placebo in Study 004 and either teduglutide 0.05 or 0.10 mg dose in Study 005, PN Use at Week 28 was compared to the use of PN at Week 24 of Study 004 to calculate the 20% reduction in PN Use.	28 weeks
Secondary	Number of Subjects Who Achieved at Least a One-Day Reduction in Parenteral Nutrition (PN) Use	Number of Subjects Who Achieved at Least a One-Day Reduction in Parenteral Nutrition (PN) Use (Responder Status is Yes or No)	6 months